TY - JOUR T1 - Chromatin accessibility changes at intergenic regions associates with ovarian cancer drug resistance JF - bioRxiv DO - 10.1101/2021.02.24.432641 SP - 2021.02.24.432641 AU - John Gallon AU - Erick Loomis AU - Edward Curry AU - Nicholas Martin AU - Leigh Brody AU - Ian Garner AU - Robert Brown AU - James M. Flanagan Y1 - 2021/01/01 UR - http://biorxiv.org/content/early/2021/02/24/2021.02.24.432641.abstract N2 - We have investigated how genomic distribution of chromatin accessibilities alter during acquisition of resistance to carboplatin-based chemotherapy using matched ovarian cell lines from high grade serous ovarian cancer (HGSOC) patients before and after becoming clinically resistant to platinum-based chemotherapy. Resistant lines show altered chromatin accessibility at intergenic regions, but less so at gene promoters. Super-enhancers, as defined by clusters of cis-regulatory elements, at these intergenic regions show chromatin changes that are associated with altered expression of linked genes, with enrichment for genes involved in the Fanconi anemia/BRCA DNA damage response pathway. Further, genome-wide distribution of platinum adducts associates with the chromatin changes observed and distinguish sensitive from resistant lines. In the resistant line, we observe fewer adducts around gene promoters and more adducts at intergenic regions. Thus, chromatin changes at intergenic regulators of gene expression are associated with in vivo derived drug resistance and Pt-adduct distribution in patient-derived HGSOC drug resistance models. ER -